<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778010</url>
  </required_header>
  <id_info>
    <org_study_id>5738</org_study_id>
    <secondary_id>R01DA023650</secondary_id>
    <nct_id>NCT01778010</nct_id>
  </id_info>
  <brief_title>Modafinil for Smoked Cocaine Self-Administration</brief_title>
  <official_title>Modafinil in a Human Laboratory Model of Cocaine Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Modafinil has been reported to reduce cocaine use in a clinical sample of infrequent users (2
      days/week), but the effects of modafinil on cocaine self-administration in the laboratory
      have not been studied. The present study investigated the effects of modafinil maintenance on
      cocaine self-administration by frequent users (4 days/week) under controlled laboratory
      conditions. During this 48-day double-blind, crossover design study, the effects of modafinil
      maintenance (0, 200, and 400mg/day) on response to smoked cocaine (0, 12, 25, and 50 mg) were
      examined in nontreatment seeking cocaine-dependent individuals (n = 8).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Self-administration</measure>
    <time_frame>48 days</time_frame>
    <description>The number of purchased cocaine doses as a function of cocaine dose and modafinil maintenance condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Quality Cluster</measure>
    <time_frame>48 days</time_frame>
    <description>Visual analogue scale ratings on the 'Drug Quality' cluster as a function of cocaine dose and modafinil maintenance condition. A cluster score was derived by taking the arithmetic average of the items in the cluster. Scores range from 0-100, with higher scores indicating greater agreement with the term. The &quot;Drug Quality Cluster&quot; consisted of three items:
&quot;the choice was of high quality&quot;
&quot;the choice was potent&quot;
&quot;I liked the choice&quot; Higher scores indicate increasing agreement with the statement, which would indicate a poorer outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>48 days</time_frame>
    <description>Values for heart rate as a function of cocaine dose and modafinil maintenance condition.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Modafinil 0mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants were maintained on modafinil (0 mg/day) for 15 days, and underwent a dose response of cocaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modafinil 200mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were maintained on modafinil (200 mg/day) for 15 days, and underwent a dose response of cocaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modafinil 400mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were maintained on modafinil (400 mg/day) for 15 days, and underwent a dose response of cocaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil 0 mg</intervention_name>
    <description>Modafinil (0 mg/day)</description>
    <arm_group_label>Modafinil 0mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil 200 mg</intervention_name>
    <description>Modafinil (200 mg/day)</description>
    <arm_group_label>Modafinil 200mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil 400 mg</intervention_name>
    <description>Modafinil (400 mg/day)</description>
    <arm_group_label>Modafinil 400mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocaine 0 mg</intervention_name>
    <description>Cocaine (0 mg/day)</description>
    <arm_group_label>Modafinil 0mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
    <arm_group_label>Modafinil 200mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
    <arm_group_label>Modafinil 400mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocaine 12 mg</intervention_name>
    <description>Cocaine (12 mg/day)</description>
    <arm_group_label>Modafinil 0mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
    <arm_group_label>Modafinil 200mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
    <arm_group_label>Modafinil 400mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocaine 25 mg</intervention_name>
    <description>Cocaine (25 mg/day)</description>
    <arm_group_label>Modafinil 0mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
    <arm_group_label>Modafinil 200mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
    <arm_group_label>Modafinil 400mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocaine 50 mg</intervention_name>
    <description>Cocaine (50 mg/day)</description>
    <arm_group_label>Modafinil 0mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
    <arm_group_label>Modafinil 200mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
    <arm_group_label>Modafinil 400mg + Cocaine 0, 12, 25, 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Smokes cocaine

          2. Has patterns of smoked cocaine use in terms of frequency and amount which parallel or
             exceed those administered in the study.

          3. Age 21-50.

          4. Able to give informed consent, and comply with study procedures.

          5. Normal body weight Within normal weight range (for appropriate frame) according to
             1983 Metropolitan Weight tables -

        Exclusion Criteria:

          1. Current seizure disorder, heart disease or a history of serious adverse effects due to
             cocaine.

          2. Dependence on substances (other than cocaine or nicotine) or a history of dependence
             on alcohol

          3. Request for drug treatment

          4. Judged to be noncompliant with study protocol.

          5. Current use of any psychotropic medication.

          6. Clinical laboratory tests outside normal limits that are clinically unacceptable to
             the study physician (BP &gt; 140/90; BUN, creatinine, LFTs &gt; 3x ULN; hematocrit &lt; 34 for
             women, &lt; 36 for men; pseudocholinesterase deficiency)

          7. History of myocardial infarction or ischemia, clinically significant left ventricular
             hypertrophy, angina, clinically significant arrhythmia, or mitral valve prolapse

          8. Currently meeting DSM-IV criteria for all major psychiatric/psychotic disorders other
             than transient psychosis due to drug abuse

          9. Current parole or probation Self-report during interview -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Haney, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYS Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2013</study_first_submitted>
  <study_first_submitted_qc>January 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <results_first_submitted>August 8, 2017</results_first_submitted>
  <results_first_submitted_qc>December 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 9, 2018</results_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cocaine</keyword>
  <keyword>modafinil</keyword>
  <keyword>self-administration</keyword>
  <keyword>DRD4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Modafinil + Cocaine</title>
          <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and underwent a dose response of smoked cocaine (0, 12, 25, and 50mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>abnormal ECG before meds</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Arrested</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>rash while on placebo</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</population>
      <group_list>
        <group group_id="B1">
          <title>Modafinil + Cocaine</title>
          <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Self-administration</title>
        <description>The number of purchased cocaine doses as a function of cocaine dose and modafinil maintenance condition.</description>
        <time_frame>48 days</time_frame>
        <population>Eight patients contributed to each condition, in a within-subjects manner.</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil 0mg + Cocaine 0mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O2">
            <title>Modafinil 200mg + Cocaine 0mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O3">
            <title>Modafinil 400mg + Cocaine 0mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O4">
            <title>Modafinil 0mg + Cocaine 12mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O5">
            <title>Modafinil 200mg + Cocaine 12mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O6">
            <title>Modafinil 400mg + Cocaine 12mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O7">
            <title>Modafinil 0mg + Cocaine 25mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O8">
            <title>Modafinil 200mg + Cocaine 25mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O9">
            <title>Modafinil 400mg + Cocaine 25mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O10">
            <title>Modafinil 0mg + Cocaine 50mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O11">
            <title>Modafinil 200mg + Cocaine 50mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O12">
            <title>Modafinil 400mg + Cocaine 50mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Self-administration</title>
          <description>The number of purchased cocaine doses as a function of cocaine dose and modafinil maintenance condition.</description>
          <population>Eight patients contributed to each condition, in a within-subjects manner.</population>
          <units>Number of doses purchased</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="2.2" spread="0.3"/>
                    <measurement group_id="O5" value="1.5" spread="0.3"/>
                    <measurement group_id="O6" value="2.1" spread="0.1"/>
                    <measurement group_id="O7" value="4.1" spread="0.2"/>
                    <measurement group_id="O8" value="2.5" spread="0.3"/>
                    <measurement group_id="O9" value="2.6" spread="0.3"/>
                    <measurement group_id="O10" value="4.5" spread="0.1"/>
                    <measurement group_id="O11" value="3.5" spread="0.3"/>
                    <measurement group_id="O12" value="3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Quality Cluster</title>
        <description>Visual analogue scale ratings on the ‘Drug Quality’ cluster as a function of cocaine dose and modafinil maintenance condition. A cluster score was derived by taking the arithmetic average of the items in the cluster. Scores range from 0-100, with higher scores indicating greater agreement with the term. The &quot;Drug Quality Cluster&quot; consisted of three items:
&quot;the choice was of high quality&quot;
&quot;the choice was potent&quot;
&quot;I liked the choice&quot; Higher scores indicate increasing agreement with the statement, which would indicate a poorer outcome.</description>
        <time_frame>48 days</time_frame>
        <population>Eight subjects participants in each condition in a within-subjects fashion.</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil 0mg + Cocaine 0mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O2">
            <title>Modafinil 200mg + Cocaine 0mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O3">
            <title>Modafinil 400mg + Cocaine 0mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O4">
            <title>Modafinil 0mg + Cocaine 12mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O5">
            <title>Modafinil 200mg + Cocaine 12mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O6">
            <title>Modafinil 400mg + Cocaine 12mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O7">
            <title>Modafinil 0mg + Cocaine 25mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O8">
            <title>Modafinil 200mg + Cocaine 25mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O9">
            <title>Modafinil 400mg + Cocaine 25mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O10">
            <title>Modafinil 0mg + Cocaine 50mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O11">
            <title>Modafinil 200mg + Cocaine 50mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O12">
            <title>Modafinil 400mg + Cocaine 50mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Quality Cluster</title>
          <description>Visual analogue scale ratings on the ‘Drug Quality’ cluster as a function of cocaine dose and modafinil maintenance condition. A cluster score was derived by taking the arithmetic average of the items in the cluster. Scores range from 0-100, with higher scores indicating greater agreement with the term. The &quot;Drug Quality Cluster&quot; consisted of three items:
&quot;the choice was of high quality&quot;
&quot;the choice was potent&quot;
&quot;I liked the choice&quot; Higher scores indicate increasing agreement with the statement, which would indicate a poorer outcome.</description>
          <population>Eight subjects participants in each condition in a within-subjects fashion.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="0.5"/>
                    <measurement group_id="O2" value="2" spread="0.5"/>
                    <measurement group_id="O3" value="2" spread="0.5"/>
                    <measurement group_id="O4" value="30" spread="5"/>
                    <measurement group_id="O5" value="28" spread="4"/>
                    <measurement group_id="O6" value="29" spread="3"/>
                    <measurement group_id="O7" value="44" spread="4"/>
                    <measurement group_id="O8" value="35" spread="4"/>
                    <measurement group_id="O9" value="35" spread="2"/>
                    <measurement group_id="O10" value="60" spread="3"/>
                    <measurement group_id="O11" value="55" spread="4"/>
                    <measurement group_id="O12" value="55" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>Values for heart rate as a function of cocaine dose and modafinil maintenance condition.</description>
        <time_frame>48 days</time_frame>
        <population>Eight patients participated in each condition in a within-subjects fashion.</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil 0mg + Cocaine 0mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O2">
            <title>Modafinil 200mg + Cocaine 0mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O3">
            <title>Modafinil 400mg + Cocaine 0mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O4">
            <title>Modafinil 0mg + Cocaine 12mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O5">
            <title>Modafinil 200mg + Cocaine 12mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O6">
            <title>Modafinil 400mg + Cocaine 12mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O7">
            <title>Modafinil 0mg + Cocaine 25mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O8">
            <title>Modafinil 200mg + Cocaine 25mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O9">
            <title>Modafinil 400mg + Cocaine 25mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O10">
            <title>Modafinil 0mg + Cocaine 50mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O11">
            <title>Modafinil 200mg + Cocaine 50mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
          <group group_id="O12">
            <title>Modafinil 400mg + Cocaine 50mg</title>
            <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>Values for heart rate as a function of cocaine dose and modafinil maintenance condition.</description>
          <population>Eight patients participated in each condition in a within-subjects fashion.</population>
          <units>BPM</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" spread="2"/>
                    <measurement group_id="O2" value="86" spread="2"/>
                    <measurement group_id="O3" value="91" spread="2"/>
                    <measurement group_id="O4" value="102" spread="3"/>
                    <measurement group_id="O5" value="101" spread="2.5"/>
                    <measurement group_id="O6" value="97" spread="3"/>
                    <measurement group_id="O7" value="130.5" spread="2"/>
                    <measurement group_id="O8" value="110" spread="3"/>
                    <measurement group_id="O9" value="115" spread="2.5"/>
                    <measurement group_id="O10" value="141" spread="2"/>
                    <measurement group_id="O11" value="125" spread="4"/>
                    <measurement group_id="O12" value="122" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Modafinil 0 mg + Cocaine (0, 12, 25, and 50mg)</title>
          <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (0 mg/day) and a dose response of four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
        </group>
        <group group_id="E2">
          <title>Modafinil 200 mg + Cocaine (0, 12, 25, and 50mg)</title>
          <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (200 mg/day) and a dose response of four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
        </group>
        <group group_id="E3">
          <title>Modafinil 400 mg + Cocaine (0, 12, 25, and 50mg)</title>
          <description>During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (400 mg/day) and a dose response of four doses of smoked cocaine (0, 12, 25, and 50mg).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study is limited by the small, non-diverse sample.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Margaret Haney, Ph.D.</name_or_title>
      <organization>New York State Psychiatric Institute at Columbia University Medical Center</organization>
      <phone>646-774-6153</phone>
      <email>meg.haney@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

